Cardiovascular safety is a leading cause of drug attrition and often emerges too late, when the costs of failure are at their highest. For drug discovery scientists, identifying cardiac liabilities early in the development pipeline is not only a scientific imperative but also a strategic necessity. Early detection enables informed decision-making, more efficient use of resources, and the opportunity to refine or deprioritise candidates before significant investment in preclinical or clinical development.

Time: 10:00 AM EDT | Format: Online | Free Registration

Extracellular vesicles (EVs), lipid bilayer-enclosed particles secreted by most cell types, are gaining increasing attention for their dualistic roles in neurodegenerative disorders. In Alzheimer's disease (AD), EVs function as both messengers of toxicity and protectors of neuronal integrity, making them critical yet complex components in disease progression and potential therapy.

To mark the 25th anniversary of the Tyndall Centre for Climate Change Research, the University of East Anglia (UEA), which leads the Tyndall Centre, is holding its largest ever climate conference. Many of the brightest minds on climate change are attending to discuss the ‘critical decade for climate action’ ahead of us and to discuss what university research needs to happen in the next five years that is truly useful for climate change action.

Join us for the upcoming o2h ChaiTime Webinar, where our expert panellists will discuss how MFN pricing could reshape R&D strategies, operations, decision-making for biotech and pharma. 

The biopharma landscape is shifting fast, driven by evolving pricing policies, geopolitical trade tensions, and mounting pressure to optimise R&D investment. With the recent push toward nation-based drug pricing, global companies are being forced to rethink not just pricing models, but where and how they innovate.